Why Odonate Therapeutics Stock Is Crashing Today | The Motley Fool

Accessibility MenuSearch for a companyAccessibility...HelpArrow-Thin-DownS&P 5006,902.05+0.6%+43.58Arrow-Thin-DownDJI48,977.18+1.2%+594.79Arrow-Thin-DownNASDAQ23,395.82+0.7%+160.19Arrow-Thin-DownBitcoin$93,762.00+1.0%+$903.67Arrow-Thin-DownXOM$125.36+2.2%+$2.71Arrow-Thin-DownCVX$163.69+5.0%+$7.79Arrow-Thin-DownRGC$27.04+31.6%+$6.50Arrow-Thin-DownMELI$2,148.62+8.9%+$174.92Arrow-Thin-DownOKLO$89.34+14.8%+$11.54Arrow-Thin-DownSMR$18.78+15.1%+$2.47Arrow-Thin-DownAMZN$233.03+2.9%+$6.53Arrow-Thin-DownGOOG$317.21+0.6%+$1.89Arrow-Thin-DownMETA$658.34+1.2%+$7.93Arrow-Thin-DownMSFT$472.67-0.1%-$0.27Arrow-Thin-DownNVDA$188.12-0.4%-$0.73Arrow-Thin-DownTSLA$451.21+3.0%+$13.14Daily Stock GainersDaily Stock LosersMost Active Stocksarrow-leftarrow-rightDaily Stock GainersDaily Stock LosersMost Active StocksBy Keith Speights – Updated Mar 22, 2021 at 11:44AM EST

OTC: ODT

Odonate

Market Cap$55BToday's Changeangle-down(-71.60%) $126040.00Current Price$50000.00Price as of February 4, 2025 at 11:27 AM ET

The company's news was so bad that it's going out of business.

What happened

Shares of Odonate Therapeutics (ODT 71.60%) were crashing 78% as of 11:38 a.m. EDT on Monday. The huge drop came after Odonate announced that it's discontinuing the development of tesetaxel and will "wind down the operations of the Company."

So what

Today's news underscores the risks involved with investing in clinical-stage biotech stocks. The risk is especially great for companies with only one pipeline candidate.

Image source: Getty Images.

Odonate had hoped that it would be able to win approval for tesetaxel after the experimental drug achieved its primary endpoint of progression-free survival in a late-stage study for treating metastatic breast cancer. However, the company met with the U.S. Food and Drug Administration (FDA) about the path for approval for the drug. After receiving feedback from the FDA, Odonate decided that the data for tesetaxel wasn't likely to win FDA approval.

Some companies try to pivot in another direction after encountering an obstacle as Odonate experienced. The problem, though, is that Odonate put all of its eggs in one basket with tesetaxel and has no other drug in its pipeline. 

Now what

Odonate said it plans to work with patients in its clinical study to transition to other therapies. After that, the company will shut down at some point in the near future.

Advertisement

Read Next

Aug 28, 2020 •By Keith SpeightsWhy Odonate Therapeutics Stock Is Soaring TodayJul 9, 2019 •By Cory RenauerHere's Why Odonate Therapeutics Stock Jumped 70.7% in JuneFeb 24, 2018 •By Keith Speights3 Biotech Stocks That Soared This Week: Are They Buys?

About the Author

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.TMFFishBiz

Stocks Mentioned

Odonate

OTC: ODT$50000.00 (0.72%) $126040.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

AdvertisementAdvertisement

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services